Published at globenewswire.com.
DENVER, July 13, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use is pleased to announce that its subsidiary Mindleap Health (“Mindleap”), is launching the 2.0 version of its virtual health platform on July 30, 2021 (see Mindleap.com), which provides the infrastructure to support the conscious and trustworthy adoption of psychedelics into the broader categories of mental health and inner wellness.
“We are providing a platform that can help transform the lives of millions of people,” said Mindleap Interim CEO & Technical Director William Cook. “Our aim is to bring conscious and trustworthy support for people on their daily mental-health journey while also supporting life-changing healing experiences.”
Mindleap is designed to support users via a number of complementary features, including a media library that contains guided meditations, sound journeys, and educational content about inner wellness and psychedelic medicines. Mindleap’s media content is developed in partnership with world-class researchers and practitioners who study and practice various aspects of psychedelic medicines and treatments, mental health, and neuroscience. Some of the guests featured on Mindleap 2.0 content include leading researchers such as David Erritzoe, MD, Ph.D. from Imperial College of London, John Cline, Ph.D. from Yale, as well as Gregory Wells, PhD, and Marcela Ot’alora G. from MAPS.
Mindleap 2.0 also features a focus on the community that allows users to get to know and learn from mental health specialists via media and written posts. Once users are ready, they can schedule and attend encrypted video support sessions via the platform and receive guidance from psychedelic integration or inner wellness specialists. Users can monitor and log various aspects of their inner wellness via the updated private health journal. Additionally, they have the option to temporarily share their health journal with a specialist during a private video support call, to help specialists develop a better understanding of how they’re doing.
“The platform provides the optimal community space for users to develop trust in and connect with support professionals,” said Nicholas Martin, Mindleap’s Director of Specialists & Community. “Users will be able to connect with integration specialists who have demonstrated experience and training from psychedelic integration training programs.”
Mindleap is also being designed to support patient care and monitoring that supports clinical trials, including those being run by Mindleap’s parent company, Mydecine Innovations Group. Together, Mindleap’s content library, health journal, community platform, video support sessions, and practice management portal make it an advanced bundled solution that is paving the way for the future of mental health.
Mydecine Innovations Group™ (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) is an emerging biotech and life sciences company dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. The company’s world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, and unique delivery systems. Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility with the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds with full government approval through Health Canada. Mydecine also operates out of a state-of-the-art mycology lab in Denver, CO to focus on genetic research for scaling commercial cultivation of rare (non-psychedelic) medicinal mushrooms.
At the heart of Mydecine’s core philosophy is that psychedelic-assisted psychotherapy will continue to gain acceptance in the medical community with many of the world’s best accredited research organizations demonstrating its remarkable clinical effectiveness. Mydecine recognizes the responsibility associated with psychedelic-assisted therapy and will continue to position itself as a long-term leader across the spectrum of clinical trials, research, technology, and global supply. Mydecine has also successfully completed multiple acquisitions since its inception.
Mindleap Health Inc., a wholly-owned subsidiary of Mydecine, is a virtual healthcare company that offers technology solutions that allow people to improve their mental health and wellbeing. Mindleap is a virtual health platform that provides our users with inner wellness resources to assist them in their daily mental-health journey. Mindleap features a community of professionals, a private health journal, and an ever-expanding content library that includes meditations and psychoeducation materials from experts in mental health. Mindleap provides the space for users to videoconference with professionals who can support them in psychedelic integration, as well as their inner wellness journeys more broadly. The Mindleap infrastructure is designed to foster the conscious and trustworthy adoption of psychedelics into a widely accepted approach to mental health and inner wellness.
For further information about Mydecine Innovations Group, Inc., please visit the Company’s profile on SEDAR at www.sedar.com or visit the Company’s website at www.mydecine.com.
This news release contains forward-looking information within the meaning of Canadian securities laws regarding the Company and its business, which relate to future events or future performance and reflect management’s current expectations and assumptions. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, risks regarding the COVID-19 pandemic, the availability and continuity of financing, the ability of the Company to adequately protect and enforce its intellectual property, the Company's ability to bring its products to commercial production, continued growth of the global adaptive pathway medicine, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company's products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation.